Authoritative review from The one and only @ghoshonthemove.bsky.social ☺️on her doctoral work on NSCLC 🫁 @mcgillgci.bsky.social portlandpress.com/biochemsoctr... Need to stay tuned to see if these mutations can generate targetable neoantigens in tricky low-TMB cancers

Why does MET exon 14 skipping matter? It is more than a mere oncogenic mutation!😱🫁 Hot off the @biochemsoc.bsky.social press where we discuss met exon 14 and beyond @mcgillgci.bsky.social portlandpress.com/biochemsoctr...

Got new #TCR-pMHC data to send our way into BATCAVE? Wanna try BATMAN to predict targets of your #TCR? We would love to hear from you! 💽Database+codes: github.com/meyer-lab-cs... 💻BATMAN software + tutorials: github.com/meyer-lab-cs... 🦇Lets decode TCR-pMHC logic, one mutation at a time🦇

Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies www.nature.com/articles/s41...

Streptomycin Targets Tumor-Initiating Cells by Disrupting the Oxidative Phosphorylation (OXPHOS) Pathway by Hélène Guillorit, @mariaduca-cnrs.bsky.social, Françoise Macari, Alexandre David et al at @cnrs.fr @inserm.fr http://dlvr.it/TKDrwY

Nature research paper: Generation of human adult hepatocyte organoids with metabolic functions https://go.nature.com/43WXrX7

Can blocking “jumping genes” treat diseases and aging? The first clinical trials are testing inhibitors of transposons, #DNA sequences that hop around the genome on their own. scim.ag/4cHvdC4